Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Maternal-Fetal Medicine · Fetal Arrhythmia

How Are Fetal Arrhythmias Causing Hydrops Treated?

At a Glance

Fetal arrhythmias causing hydrops are primarily treated using transplacental therapy, where the pregnant mother takes anti-arrhythmic medications like sotalol or flecainide. These drugs cross the placenta to normalize the baby's heart rate, allowing the dangerous fluid buildup to slowly resolve.

Doctors treat fetal heart rhythm problems (arrhythmias) during pregnancy by prescribing anti-arrhythmic medications to the mother [1]. Because the mother and baby share a blood supply through the placenta, medications taken by the pregnant mother travel into her bloodstream, cross the placenta, and enter the baby’s circulation [2]. This approach, called transplacental therapy, allows doctors to regulate the baby’s heart rate without having to perform surgery [3]. Once the baby’s heart rhythm normalizes and the heart pumps effectively again, the fluid buildup (hydrops) often resolves completely, allowing the pregnancy to safely continue [4].

How the Medications Are Chosen

The specific medication depends on the exact type of abnormal rhythm the baby has (such as supraventricular tachycardia or atrial flutter) and the severity of the hydrops [5].

  • Flecainide and Sotalol: These are often the most effective first-line choices when hydrops fetalis is already present [6][7]. Studies show that sotalol crosses the placenta very easily, with nearly all of the medication reaching the baby [2].
  • Digoxin: While historically common, digoxin has a harder time crossing the placenta [2]. When hydrops is present, the extra fluid can act as a physical barrier, making digoxin less effective on its own [8].
  • Combination Therapy: Because hydrops makes treating the arrhythmia more difficult, doctors frequently prescribe a combination of medications (such as digoxin alongside flecainide or sotalol) to successfully lower the baby’s heart rate [9][10].

What This Means for You

Because you are the vital bridge to your baby’s treatment, you will be taking potent heart medications that your own body does not necessarily need. For this reason, your safety is a top priority.

When you first start taking these medications, you will likely be admitted to the hospital for a few days so doctors can monitor your heart continuously while they find the right dose [11]. You will be cared for closely by both a maternal-fetal medicine specialist and a cardiologist. This involves regular electrocardiograms (ECGs) to watch your own heart rhythm, as medications like sotalol and flecainide can affect it [12]. You will also need frequent blood tests to check medication levels and ensure they remain safe and effective, as the way your body processes drugs changes throughout the third trimester [13][14].

Warning Signs to Watch For:
Even after you go home, you must pay close attention to how you feel. Seek immediate medical attention or go to the emergency room if you experience:

  • Heart palpitations (feeling like your heart is racing, fluttering, or skipping beats)
  • Fainting or severe dizziness
  • Shortness of breath
  • Unexplained extreme fatigue or weakness

When Maternal Medication Isn’t Enough

In some severe cases, the hydrops fluid buildup is so significant that it prevents enough medication from crossing the placenta [8]. If the baby’s heart rhythm does not improve with maternal pills or IV medications, doctors may consider direct fetal therapy [15]. This involves carefully injecting the anti-arrhythmic medication directly into the baby’s umbilical vein or muscle using ultrasound guidance [15][16].

Success Rates and What to Expect

When anti-arrhythmic treatment successfully converts the baby’s heartbeat back to a normal rhythm, the outcome is generally excellent [3]. Early diagnosis and treatment are linked to higher success rates, allowing the baby’s heart to recover and giving the baby time to grow to a later gestational age before delivery [17].

Expected Timeline:
While every pregnancy is different, doctors typically hope to see the baby’s heart rate slow down and respond to the medication within a few days of reaching the correct dose [4]. However, the fluid buildup (hydrops) takes much longer to disappear. It is normal for the fluid to take several weeks to slowly drain and resolve completely after the heart rhythm has been fixed [3].

Common questions in this guide

How do doctors give heart medication to a baby in the womb?
Doctors typically treat the baby by prescribing anti-arrhythmic medications to the pregnant mother. Because the mother and baby share a blood supply, the medication travels through the mother's bloodstream, crosses the placenta, and safely reaches the baby's heart.
Which medications are used to treat fetal arrhythmias with hydrops?
First-line choices for treating fetal arrhythmias complicated by hydrops often include flecainide and sotalol, as these cross the placenta effectively. In severe cases, doctors may use a combination of medications, such as adding digoxin, to successfully lower the baby's heart rate.
Why do I need to be admitted to the hospital to start fetal heart medication?
You will likely be admitted to the hospital for a few days so doctors can closely monitor your own heart while finding the right medication dose for the baby. These are potent heart medications that can affect your rhythm, so continuous ECG monitoring ensures your safety.
What happens if the medication cannot cross the placenta because of the hydrops?
If severe fluid buildup prevents enough medication from reaching the baby through the placenta, doctors may consider direct fetal therapy. This procedure uses ultrasound guidance to inject the heart medication directly into the baby's umbilical vein or muscle.
How long does it take for fetal hydrops to go away after treatment starts?
While the baby's heart rate may respond to the medication within a few days, the hydrops fluid buildup takes much longer to disappear. It is normal for the fluid to take several weeks to slowly and completely drain after the heart rhythm has normalized.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific type of arrhythmia does my baby have, and which medication or combination of medications do you recommend first?
  2. 2.Will I need to be admitted to the hospital to start this medication, and if so, for how long?
  3. 3.How frequently will my own heart and medication blood levels be monitored once I go home?
  4. 4.What is our backup plan if the medication doesn't cross the placenta well enough to lower the baby's heart rate?
  5. 5.How often will we do ultrasounds to check if the fluid (hydrops) is resolving?
  6. 6.Will I need to stop or change these medications before delivery, and will the baby need heart medication after birth?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Fetal arrhythmias: Ten years' experience and review of the literature.

    Ekici H, Ökmen F, İmamoğlu M, et al.

    Turkish journal of obstetrics and gynecology 2022; (19(4)):302-307 doi:10.4274/tjod.galenos.2022.61818.

    PMID: 36511630
  2. 2

    Transplacental Therapeutic Drug Monitoring in Pregnant Women with Fetal Tachyarrhythmia Using HPLC-MS/MS.

    Starodubtseva N, Kindysheva S, Potapova A, et al.

    International journal of molecular sciences 2023; (24(3)) doi:10.3390/ijms24031848.

    PMID: 36768172
  3. 3

    Complete resolution of arrhythmia-induced hydrops fetalis in utero.

    Narayanan M, Dhuka S, Alapati S, Kauffman RP

    BMJ case reports 2020; (13(10)) doi:10.1136/bcr-2020-235827.

    PMID: 33040036
  4. 4

    Fetal Supraventricular Tachycardia: What Do We Know up to This Day?

    Tsokkou S, Konstantinidis I, Anastasiou V, et al.

    Journal of personalized medicine 2025; (15(8)) doi:10.3390/jpm15080341.

    PMID: 40863402
  5. 5

    Fetal arrhythmias: diagnosis and treatment.

    Yuan SM

    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2020; (33(15)):2671-2678 doi:10.1080/14767058.2018.1555804.

    PMID: 30879368
  6. 6

    Transplacental treatment of fetal tachycardia: A systematic review and meta-analysis.

    Hill GD, Kovach JR, Saudek DE, et al.

    Prenatal diagnosis 2017; (37(11)):1076-1083 doi:10.1002/pd.5144.

    PMID: 28833310
  7. 7

    First-Line Antiarrhythmic Transplacental Treatment for Fetal Tachyarrhythmia: A Systematic Review and Meta-Analysis.

    Alsaied T, Baskar S, Fares M, et al.

    Journal of the American Heart Association 2017; (6(12)) doi:10.1161/JAHA.117.007164.

    PMID: 29246961
  8. 8

    Antenatal antiarrhythmic treatment for fetal tachyarrhythmias: a study protocol for a prospective multicentre trial.

    Miyoshi T, Maeno Y, Sago H, et al.

    BMJ open 2017; (7(8)):e016597 doi:10.1136/bmjopen-2017-016597.

    PMID: 28851790
  9. 9

    Efficacy and Safety of Various First-Line Therapeutic Strategies for Fetal Tachycardias: A Network Meta-Analysis and Systematic Review.

    Qin J, Deng Z, Tang C, et al.

    Frontiers in pharmacology 2022; (13()):935455 doi:10.3389/fphar.2022.935455.

    PMID: 35770083
  10. 10

    Favourable outcome for hydrops or cardiac failure associated with fetal tachyarrhythmia: a 20-year review.

    Tunca Sahin G, Beattie RB, Uzun O

    Cardiology in the young 2022; (32(7)):1077-1084 doi:10.1017/S104795112100367X.

    PMID: 34551832
  11. 11

    Treatment of Fetal Arrhythmias.

    Veduta A, Panaitescu AM, Ciobanu AM, et al.

    Journal of clinical medicine 2021; (10(11)) doi:10.3390/jcm10112510.

    PMID: 34204066
  12. 12

    Digoxin Therapy of Fetal Superior Ventricular Tachycardia: Are Digoxin Serum Levels Reliable?

    Saad AF, Monsivais L, Pacheco LD

    AJP reports 2016; (6(3)):e272-6 doi:10.1055/s-0036-1586241.

    PMID: 27516921
  13. 13

    Maternal effects induced by oral digoxin during treatment of fetal tachyarrhythmia: Case series and literature review.

    Chimenea Á, García-Díaz L, Méndez A, Antiñolo G

    European journal of obstetrics, gynecology, and reproductive biology 2021; (256()):354-357 doi:10.1016/j.ejogrb.2020.11.055.

    PMID: 33276280
  14. 14

    Transition of maternal serum concentration of digoxin and flecainide in the third trimester-A case report of fetal supraventricular tachycardia with hydrops.

    Takatsuka H, Wakabayashi K, Yamazaki S, et al.

    Clinical case reports 2021; (9(5)):e03992 doi:10.1002/ccr3.3992.

    PMID: 34026129
  15. 15

    Multiple direct fetal amiodarone administration for supraventricular tachycardia with hydrops fetalis: a case report.

    Adenin I, Kapnosa Hasani RD

    European heart journal. Case reports 2023; (7(4)):ytad128 doi:10.1093/ehjcr/ytad128.

    PMID: 37057279
  16. 16

    Fetal Intervention for Refractory Supraventricular Tachycardia Complicated by Hydrops Fetalis.

    Munoz JL, Lewis AL, Song J, Ramsey PS

    Case reports in obstetrics and gynecology 2022; (2022()):5148250 doi:10.1155/2022/5148250.

    PMID: 35313721
  17. 17

    Prenatal diagnosis and management of fetal supraventricular tachyarrhythmia and postnatal outcomes.

    Demirci O, Tosun Ö, Bolat G

    Journal of gynecology obstetrics and human reproduction 2022; (51(3)):102323 doi:10.1016/j.jogoh.2022.102323.

    PMID: 35063720

This page explains general treatment approaches for fetal arrhythmias and hydrops for educational purposes. Always consult your maternal-fetal medicine specialist for decisions regarding your specific pregnancy and medications.

Get notified when new evidence is published on Non-immune hydrops fetalis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.